Compare KMX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMX | LQDA |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.5B |
| IPO Year | 2002 | 2020 |
| Metric | KMX | LQDA |
|---|---|---|
| Price | $46.79 | $68.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | $37.18 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 3.2M | 1.8M |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 1.68 | 0.52 |
| Revenue | ★ $25,881,131,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $278.87 |
| Revenue Next Year | $1.82 | $57.13 |
| P/E Ratio | ★ $31.02 | $130.79 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $30.40 | $11.85 |
| 52 Week High | $71.99 | $73.22 |
| Indicator | KMX | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 67.42 |
| Support Level | $42.97 | $31.99 |
| Resistance Level | $49.66 | N/A |
| Average True Range (ATR) | 2.23 | 4.55 |
| MACD | 0.32 | 0.10 |
| Stochastic Oscillator | 36.04 | 76.49 |
CarMax sells, finances, and services used and new cars through a chain of over 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 83% of fiscal 2025 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2025, the company retailed and wholesaled 789,050 and 544,312 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in calendar 2024. It seeks over 5% share. CarMax is based in Richmond, Virginia.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.